Daily Stock Analysis, CAPR, Capricor Therapeutics Inc, priceseries

Capricor Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.43
Close
0.41
High
0.45
Low
0.40
Previous Close
0.42
Daily Price Gain
-0.01
YTD High
0.74
YTD High Date
Jan 24, 2019
YTD Low
0.40
YTD Low Date
Feb 14, 2019
YTD Price Change
-0.08
YTD Gain
-16.65%
52 Week High
2.11
52 Week High Date
Feb 15, 2018
52 Week Low
0.31
52 Week Low Date
Dec 27, 2018
52 Week Price Change
-1.59
52 Week Gain
-79.37%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 13. 2017
2.82
Feb 23. 2017
2.96
7 Trading Days
5.02%
Link
LONG
Jul 18. 2017
1.36
Jul 19. 2017
1.45
1 Trading Days
6.25%
Link
LONG
Sep 18. 2017
1.32
Oct 9. 2017
2.53
15 Trading Days
91.69%
Link
LONG
Nov 10. 2017
2.47
Nov 15. 2017
2.65
3 Trading Days
7.29%
Link
LONG
Feb 2. 2018
1.91
Feb 5. 2018
2.08
1 Trading Days
8.90%
Link
Company Information
Stock Symbol
CAPR
Exchange
NasdaqCM
Company URL
http://www.capricor.com
Company Phone
(310) 358-3200
CEO
Linda Marbán
Headquarters
California
Business Address
8840 WILSHIRE BLVD, 2ND FLOOR, BEVERLY HILLS, CA 90211
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001133869
About

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on November 20, 2013 and is headquartered in Beverly Hills, CA.

Description

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.